Indeed, a regulatory axis was proposed that involves the ATF4 transcription factor and its coactivator NCOA3 as a direct DYRK3 substrate, regulating the expression of key metabolic enzymes in the purine synthesis pathway that are relevant to HCC progression. The gene discussed is DYRK3; the disease is hepatocellular carcinoma.